Drug interactions
Lorlatinib + Regorafenib
Severity: Moderate
Lorlatinib and Regorafenib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib is a moderate inducer of CYP3A4 and may lower exposure to regorafenib and its active metabolites. This could reduce antitumor efficacy of regorafenib.
What this interaction means in plain words
Lorlatinib and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Lorlatinib belongs to Oncology; Regorafenib belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4, increasing the metabolism of regorafenib.
What to do
Monitor for reduced regorafenib efficacy and consider an alternative if loss of response is suspected. Reassess therapy if lorlatinib is started or stopped.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Regorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Regorafenib
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Lorlatinib with Regorafenib?
MediHelp rates the interaction as moderate. Lorlatinib and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib is a moderate inducer of CYP3A4 and may lower exposure to regorafenib and its active metabolites. This could reduce antitumor efficacy of regorafenib.
How serious is the interaction between Lorlatinib and Regorafenib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for reduced regorafenib efficacy and consider an alternative if loss of response is suspected. Reassess therapy if lorlatinib is started or stopped.
What other medicines interact with Regorafenib?
MediHelp also lists interactions of Regorafenib with, for example, Apalutamide, Atazanavir, Carbamazepine. The full list is on the Regorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
